TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • September 24, 2019

THOUSAND OAKS, CA—Amgen, a California-based biopharmaceutical company, has acquired the worldwide rights to Otezla (apremilast) from Celegene, Summit, NJ. Otezla is the only oral, non-biologic treatment for psoriasis and psoriatic arthritis. The acquisition is a result of Celegene’s impending merger with Bristol-Myers Squibb, New York, NY.